CA83705/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2000	1
2001	4
2002	5
2003	5
2004	3
2021	0

1

Apoptosis regulators.

Harada H, Grant S. Harada H, et al. Rev Clin Exp Hematol. 2003 Jun;7(2):117-38. Rev Clin Exp Hematol. 2003. PMID: 14763159 Review.

2

Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.

Dent P, Grant S. Dent P, et al. Clin Cancer Res. 2001 Apr;7(4):775-83. Clin Cancer Res. 2001. PMID: 11309321 Free article. Review. No abstract available.

3

The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.

Ahmed W, Rahmani M, Dent P, Grant S. Ahmed W, et al. Cell Cycle. 2004 Oct;3(10):1305-11. doi: 10.4161/cc.3.10.1161. Epub 2004 Oct 6. Cell Cycle. 2004. PMID: 15467449

4

A novel assay for the measurement of Raf-1 kinase activity.

Bondzi C, Grant S, Krystal GW. Bondzi C, et al. Oncogene. 2000 Oct 12;19(43):5030-3. doi: 10.1038/sj.onc.1203862. Oncogene. 2000. PMID: 11042690

5

Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.

Wang S, Wang Z, Grant S. Wang S, et al. Mol Pharmacol. 2003 Jan;63(1):232-42. doi: 10.1124/mol.63.1.232. Mol Pharmacol. 2003. PMID: 12488556

6

MEK1/2 inhibitors promote Ara-C-induced apoptosis but not loss of Deltapsi(m) in HL-60 cells.

Yu C, Wang Z, Dent P, Grant S. Yu C, et al. Biochem Biophys Res Commun. 2001 Sep 7;286(5):1011-8. doi: 10.1006/bbrc.2001.5513. Biochem Biophys Res Commun. 2001. PMID: 11527401

7

Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.

McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, Dent P. McKinstry R, et al. Cancer Biol Ther. 2002 May-Jun;1(3):243-53. doi: 10.4161/cbt.75. Cancer Biol Ther. 2002. PMID: 12432271

8

The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.

Yu C, Rahmani M, Dent P, Grant S. Yu C, et al. Exp Cell Res. 2004 May 1;295(2):555-66. doi: 10.1016/j.yexcr.2004.02.001. Exp Cell Res. 2004. PMID: 15093752

9

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.

Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Dai Y, et al. Blood. 2004 Jul 15;104(2):509-18. doi: 10.1182/blood-2003-12-4121. Epub 2004 Mar 23. Blood. 2004. PMID: 15039284

10

Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

Rosato RR, Almenara JA, Dai Y, Grant S. Rosato RR, et al. Mol Cancer Ther. 2003 Dec;2(12):1273-84. Mol Cancer Ther. 2003. PMID: 14707268 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results